Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have been assigned an average rating of “Hold” from the thirteen research firms that are currently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $33.67.

VNDA has been the topic of a number of research reports. Citigroup lowered shares of BCE from a “buy” rating to a “neutral” rating in a report on Thursday, May 2nd. Oppenheimer set a $18.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “hold” rating in a report on Sunday, May 5th. BidaskClub lowered shares of Intersect ENT from a “hold” rating to a “sell” rating in a report on Thursday, April 11th. Zacks Investment Research upgraded shares of SCHNEIDER ELEC /ADR from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a report on Friday, July 5th. Finally, ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd.

In other news, CEO Mihael Hristos Polymeropoulos sold 72,872 shares of the firm’s stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $15.34, for a total value of $1,117,856.48. Following the sale, the chief executive officer now directly owns 1,276,343 shares in the company, valued at approximately $19,579,101.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 8.20% of the stock is currently owned by company insiders.

Large investors have recently made changes to their positions in the stock. Metropolitan Life Insurance Co. NY raised its stake in Vanda Pharmaceuticals by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 17,187 shares of the biopharmaceutical company’s stock worth $449,000 after acquiring an additional 13,423 shares in the last quarter. Squarepoint Ops LLC raised its stake in Vanda Pharmaceuticals by 50.4% during the 4th quarter. Squarepoint Ops LLC now owns 161,884 shares of the biopharmaceutical company’s stock worth $4,230,000 after acquiring an additional 54,269 shares in the last quarter. Strs Ohio raised its stake in Vanda Pharmaceuticals by 28.4% during the 1st quarter. Strs Ohio now owns 42,500 shares of the biopharmaceutical company’s stock worth $782,000 after acquiring an additional 9,400 shares in the last quarter. Candriam Luxembourg S.C.A. acquired a new stake in Vanda Pharmaceuticals during the 4th quarter worth $4,651,000. Finally, Geode Capital Management LLC raised its stake in Vanda Pharmaceuticals by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 596,626 shares of the biopharmaceutical company’s stock worth $15,588,000 after acquiring an additional 6,666 shares in the last quarter. Hedge funds and other institutional investors own 99.33% of the company’s stock.

Vanda Pharmaceuticals stock traded down $0.32 during mid-day trading on Tuesday, reaching $12.99. 642,156 shares of the company’s stock were exchanged, compared to its average volume of 676,973. The firm has a market capitalization of $688.00 million, a P/E ratio of 32.47 and a beta of 0.42. Vanda Pharmaceuticals has a twelve month low of $12.73 and a twelve month high of $33.44. The stock’s fifty day simple moving average is $14.08.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.07 by ($0.08). The business had revenue of $47.71 million for the quarter, compared to analyst estimates of $51.74 million. Vanda Pharmaceuticals had a return on equity of 8.07% and a net margin of 10.92%. Vanda Pharmaceuticals’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.14 earnings per share. On average, equities research analysts predict that Vanda Pharmaceuticals will post 0.06 earnings per share for the current year.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

See Also: What is an SEC Filing?

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.